Fernando Aranda

List of Publications by Citations

58 papers	2,965 citations	28 h-index	54 g-index
64 ext. papers	3,542 ext. citations	7.9 avg, IF	4.36 L-index

#	Paper	IF	Citations
58	Consensus guidelines for the detection of immunogenic cell death. *OncoImmunology*, **2014**, 3, e955691	7.2	524
57	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
56	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. *Cancer Cell*, **2016**, 30, 147-160	24.3	285
55	Trial watch: IDO inhibitors in cancer therapy. *OncoImmunology*, **2014**, 3, e957994	7.2	166
54	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. *OncoImmunology*, **2015**, 4, e1008866	7.2	162
53	Trial Watch: Chemotherapy with immunogenic cell death inducers. *OncoImmunology*, **2014**, 3, e27878	7.2	116
52	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. *OncoImmunology*, **2014**, 3, e27297	7.2	86
51	Trial Watch: Peptide vaccines in cancer therapy. *OncoImmunology*, **2013**, 2, e26621	7.2	84
50	Trial Watch-Oncolytic viruses and cancer therapy. *OncoImmunology*, **2016**, 5, e1117740	7.2	76
49	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. *OncoImmunology*, **2015**, 4, e1008814	7.2	68
48	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. *OncoImmunology*, **2014**, 3, e27048	7.2	64
47	Trial Watch: Toll-like receptor agonists in oncological indications. *OncoImmunology*, **2014**, 3, e29179	7.2	61
46	Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. *Cancer Research*, **2011**, 71, 3214-24	10.1	56
45	Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. *Oncogene*, **2015**, 34, 3053-62	9.2	54
44	Trial watch: Dendritic cell-based anticancer therapy. *OncoImmunology*, **2014**, 3, e963424	7.2	54
43	Trial watch: Immune checkpoint blockers for cancer therapy. *OncoImmunology*, **2017**, 6, e1373237	7.2	53
42	Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. *Cancer Research*, **2011**, 71, 812-21	10.1	53

41	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. *OncoImmunology*, **2016**, 5, e1214790	7.2	51
40	Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. *International Journal of Cancer*, **2009**, 125, 2614-23	7.5	51
39	Trial watch: Immunostimulatory cytokines in cancer therapy. *OncoImmunology*, **2014**, 3, e29030	7.2	47
38	Myeloid-derived cells are key targets of tumor immunotherapy. *OncoImmunology*, **2014**, 3, e28398	7.2	44
37	CD6 modulates thymocyte selection and peripheral T cell homeostasis. *Journal of Experimental Medicine*, **2016**, 213, 1387-97	16.6	43
36	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. *OncoImmunology*, **2016**, 5, e1149674	7.2	41
35	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. *Nature Communications*, **2020**, 11, 3819	17.4	41
34	Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. *Cell Metabolism*, **2019**, 30, 754-767.e9	24.6	40
33	Trial Watch-Immunostimulation with cytokines in cancer therapy. *OncoImmunology*, **2016**, 5, e1115942	7.2	35
32	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. *OncoImmunology*, **2014**, 3, e28344	7.2	30
31	Impact of myeloid cells on the efficacy of anticancer chemotherapy. *Current Opinion in Immunology*, **2014**, 30, 24-31	7.8	28
30	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. *OncoImmunology*, **2018**, 7, e1433982	7.2	23
29	Trial Watch: Adoptive cell transfer for oncological indications. *OncoImmunology*, **2015**, 4, e1046673	7.2	22
28	Trial watch: Naked and vectored DNA-based anticancer vaccines. *OncoImmunology*, **2015**, 4, e1026531	7.2	22
27	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. *Journal of Hepatology*, **2015**, 63, 329-36	13.4	18
26	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1. *European Journal of Immunology*, **2017**, 47, 1108-1118	6.1	14
25	Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. *OncoImmunology*, **2016**, 5, e1075113	7.2	14
24	CD5 as a Target for Immune-Based Therapies. *Critical Reviews in Immunology*, **2015**, 35, 85-115	1.8	14

23	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. *OncoImmunology*, **2014**, 3, e955685	7.2	13
22	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. *Cellular and Molecular Immunology*, **2018**, 15, 898-906	15.4	11
21	Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases. *PLoS ONE*, **2014**, 9, e96799	3.7	10
20	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. *International Journal of Cancer*, **2016**, 139, 1297-302	7.5	10
19	Immune effectors responsible for the elimination of hyperploid cancer cells. *OncoImmunology*, **2018**, 7, e1463947	7.2	9
18	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. *Frontiers in Immunology*, **2017**, 8, 594	8.4	8
17	Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	7
16	Gut microbiota metabolites for sweetening type I diabetes. *Cellular and Molecular Immunology*, **2018**, 15, 92-95	15.4	7
15	Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. *OncoImmunology*, **2016**, 5, e1196309	7.2	7
14	Immunomodulatory effects of soluble CD5 on experimental tumor models. *Oncotarget*, **2017**, 8, 108156-108169	5.9	7
13	Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. *Oncotarget*, **2017**, 8, 5247-5255	3.3	6
12	Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents. *Cells*, **2020**, 9,	7.9	5
11	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-□ *Journal of Immunology*, **2019**, 203, 696-704	5.3	4
10	Multifaceted effects of soluble human CD6 in experimental cancer models **2020**, 8,		4
9	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy **2021**, 9,		3
8	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. *Translational Lung Cancer Research*, **2020**, 9, 1074-1083	4.4	3
7	Transforming growth factor beta (TGF-□activity in immuno-oncology studies. *Methods in Enzymology*, **2020**, 636, 129-172	1.7	3
6	Novel strategies exploiting interleukin-12 in cancer immunotherapy.. *Pharmacology & Therapeutics*, **2022**, 239, 108189	13.9	3

5	Production and use of adeno-associated virus vectors as tools for cancer immunotherapy. *Methods in Enzymology*, **2020**, 635, 185-203	1.7	2
4	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. *Cancers*, **2021**, 13,	6.6	1
3	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. *Frontiers in Immunology*, **2020**, 11, 620283	8.4	0
2	Transgenic Tumor Models for Evaluating CAR T-Cell Immunotherapies. *Current Protocols in Pharmacology*, **2019**, 86, e66	4.1	
1	Firefighters for the Wrong Type of Inflammation in Tumors. *Cancer Discovery*, **2021**, 11, 2372-2374	24.4	